The Institute for Clinical and Economic Review (ICER) has posted draft scoping documents that will inform reports on two new drugs for diabetes (types 1 and 2) and asthma. These reports will serve as the basis for the February 12, 2016 public meeting of the California Technology Assessment Forum (CTAF), a core program of ICER. The documents will be open to public comment until 5:00 PM PT October 20.
Providing credible, evidence-based information about medical technologies, treatments, and models of care
The California Technology Assessment Forum (CTAF), a core program of the Institute for Clinical and Economic Review (ICER), reviews objective evidence reports and holds public meetings to develop recommendations for how stakeholders can apply evidence to improve the quality and value of health care.
October 29, 2015
CardioMEMS™ HF System (St. Jude Medical) and Sacubitril/Valsartan (Entresto™, Novartis) for Management of Congestive Heart Failure
February 12, 2016
Insulin Degludec (Tresiba®, Novo Nordisk) for Diabetes and Mepolizumab (Nucala®, GlaxoSmithKline) for Asthma
Bay Area TBA
Sign up to receive email notifications of upcoming CTAF meetings and new assessments. All fields required.